Home » Newsletters » BioWorld Science

BioWorld Science

July 26, 2004

View Archived Issues

Phase I studies evaluate the effects of SPD-754 on the metabolism of other anti-HIV drugs

Novel class of HIV-1 entry inhibitors targets gp120-binding domain of CD4

A recombinant vaccine shows promise in the prevention of SARS

Signet outlines plans for efforts in sepsis and acute renal failure

Celera Genomics and Seattle Genetics to develop antibody therapies for cancer

Several drugs show efficacy in the treatment of HIV-associated lipodystrophy

Hypocholesterolemic compound reduces Abeta levels in vivo

PBI-1393 activates CTLs and induces IL-2 and IFN-gamma synthesis

Flurbiprofen analogues reduce beta-amyloid release without affecting COX-1 activity

FDA to grant additional six months pediatric exclusivity to clofarabine

AzaSite enters two phase III studies for acute bacterial conjunctivitis

ViroPharma to advance maribavir into phase II

Atrix licenses BEMA technology to Arius

Pfizer to discontinue development of sumanirole

Access updates progress of AP-5346

DMAG enters phase I

Evotec to support Morphochem's development of Oxaquin

NEC discovers new peptide-vaccine candidates for hepatitis C

LY-450139 reported to reduce the levels of amyloid beta in plasma and CSF

Farnesoid X receptor agonists

New JNK3 inhibitors with potential utility in cerebral ischemia

Selective 5-HT6 antagonists claimed by Roche

Prodrugs of MPV-2426 described by Orion

Boehringer Ingelheim discloses anti-HIV agents

Glucokinase activators described by Novartis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...